LITHIUM CITRATE
LITHIUM CITRATE
Approval overview LITHIUM CITRATE is listed in Drugs@FDA under application 018421 (NDA).
Review priority: STANDARD Marketing status: Discontinued Active ingredient LITHIUM CITRATE Form and strength SYRUP;ORAL - EQ 300MG CARBONATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor HIKMA Submission history Latest submission status date: 2022-10-13 00:00:00.
Structured Monograph
Clinical summary
Approval overview LITHIUM CITRATE is listed in Drugs@FDA under application 018421 (NDA). Review priority: STANDARD Marketing status: Discontinued Active ingredient LITHIUM CITRATE Form and strength SYRUP;ORAL - EQ 300MG CARBONATE/5ML **Federal Register determination that product was not discontinued or withdrawn for safety or effectiveness reasons** Sponsor HIKMA Submission history Latest submission status date: 2022-10-13 00:00:00. Submission type: SUPPL.
Monitoring
- • Marketing status: Discontinued
- • Review priority: STANDARD
Interaction Notes
- No interaction notes stored yet.